20 completed, 8 unknown, 3 recruiting, 3 withdrawn. 13 Phase 3, 8 Phase 4, 5 Phase 2, 2 Phase 1, 1 Early Phase 1.
Follow rt-PA: new trials by email Literature Review of rt-PA trials Research Report on rt-PA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Observational Study to Assess the Safety of rhTNK-tPA (Mingfule®) vs. Rt-PA (Actilyse®) in Treating Acute Ischemic Stroke rhTNK-tPA, rt-PA - Acute Ischemic Stroke, rhTNK-tPA | Not yet recruiting | CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | 4500 | 2026-04-10 | 2026-04-09 | |
| Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial rt-PA, DAPT - Lacunar Stroke, Stroke | Phase 4 | Recruiting | Nippon Medical School | 500 | 2025-08-01 | 2026-08-04 |
| Study on Hibernation-like Therapy Based on Mechanical Thrombectomy chlorpromazine and promethazine, Placebo group, endovascular thrombectomy - Acute Ischemic Stroke | Phase 1 | Recruiting | Capital Medical University | 32 | 2024-11-09 | 2024-12-20 |
| Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 Tenecteplase, Best Practice (which may include intravenous Alteplase) - Ischemic Stroke, Acute | Phase 3 | Completed | Beijing Tiantan Hospital | 452 | 2024-01-24 | 2025-11-26 |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion Alteplase, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-08-17 | 2026-08-17 |
| Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China Tenecteplase, Alteplase - Ischemic Stroke | Unknown | Huashan Hospital | 1200 | 2023-04-02 | 2023-10-12 | |
| rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) rhPro-UK, rt-PA - Acute Ischemic Stroke | Phase 3 | Completed | Tasly Biopharmaceuticals Co., Ltd. | 1552 | 2023-01-29 | 2024-07-26 |
| Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization rt-PA - Stroke | Completed | Boehringer Ingelheim | 113035 | 2022-11-30 | 2024-12-20 | |
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） Alteplase, Tenecteplase - Acute Ischemic Stroke | Phase 3 | Unknown | Beijing Tiantan Hospital | 1630 | 2022-10-26 | 2023-02-27 |
| Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients rt-PA - Stroke | Completed | Boehringer Ingelheim | 3058 | 2022-07-18 | 2024-10-17 | |
| 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients rt-PA - Stroke | Completed | Boehringer Ingelheim | 12551 | 2022-04-12 | 2024-10-16 | |
| A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator - Acute Ischemic Stroke | Phase 3 | Completed | Angde Biotech Pharmaceutical Co., Ltd. | 1412 | 2022-03-21 | 2024-03-04 |
| Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ rt-PA, rhTNK-tPA - Acute Ischemic Stroke | Phase 3 | Completed | Beijing Tiantan Hospital | 1430 | 2021-06-12 | 2023-01-17 |
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II） Alteplase, Tenecteplase - Acute Ischemic Stroke | Phase 2 | Unknown | Beijing Tiantan Hospital | 225 | 2021-05-02 | 2022-03-31 |
| Argatroban Plus R-tPA for Acute Ischemic Stroke rt-PA, Argatroban - Stroke | Phase 4 | Completed | General Hospital of Shenyang Military Region | 808 | 2018-12-21 | 2022-02-22 |
| Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI） Argatroban combined with rt-PA, rt-PA - Argatroban, Rt-PA | Phase 4 | Terminated | Hui-Sheng Chen | 3 | 2018-07-11 | 2018-11-14 |
| Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial Recombinant tissue plasminogen activator (rt-PA), Standard Anticoagulation Therapy - Deep Vein Thrombosis, Post-Thrombotic Syndrome | Phase 3 | Withdrawn | University of Colorado, Denver | 2018-07-01 | 2018-08-10 | |
| Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) Recombinant human urokinase, Alteplase - Acute Ischaemic Stroke | Phase 3 | Completed | Tasly Biopharmaceuticals Co., Ltd. | 674 | 2018-05-18 | 2020-06-22 |
| Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion rt-PA, tenecteplase - Nervous System Disorders, Cerebral Artery | Phase 2 | Withdrawn | University Hospital Center of Martinique | 2016-07-01 | 2018-06-21 | |
| The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI rhTNK-tPA, alteplase - Acute ST Elevation Myocardial Infarction | Phase 4 | Completed | CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. | 818 | 2016-05-01 | 2022-05-25 |
Showing 20 of 36. Sign in to see all of them.
Ischemic Stroke (13) · Stroke (13) · Thrombosis (5) · Cerebral Hemorrhage (2) · Myocardial Infarction (2) · Postthrombotic Syndrome (2) · Pulmonary Embolism (2) · Venous Thrombosis (2) · Brain Infarction (1) · Hematologic Neoplasms (1) · Intracranial Hemorrhage, Hypertensive (1) · Intracranial Hemorrhages (1) · Ischemia (1) · Nervous System Diseases (1) · Postphlebitic Syndrome (1)
Beijing Tiantan Hospital (4) · Boehringer Ingelheim (4) · Johns Hopkins University (3) · Beijing Chao Yang Hospital (2) · CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. (2) · Tasly Biopharmaceuticals Co., Ltd. (2) · Angde Biotech Pharmaceutical Co., Ltd. (1) · Capital Medical University (1) · Centre Hospitalier du Centre du Valais (1) · General Hospital of Shenyang Military Region (1) · Huashan Hospital (1) · Hui-Sheng Chen (1) · M.D. Anderson Cancer Center (1) · National Cerebral and Cardiovascular Center, Japan (1) · Nippon Medical School (1)
China (21) · United States (7) · Canada (4) · Germany (4) · United Kingdom (4) · Spain (3) · Hungary (2) · Israel (2) · Japan (2) · Switzerland (2) · Australia (1) · Belgium (1) · Brazil (1) · Denmark (1) · France (1)
Daniel F. Hanley, MD (2) · Shuya Li (2) · Yongjun Wang, MD (2) · Arthur M Pancioli, MD (1) · Ben He, MD (1) · Bruce Campbell, MD, PhD (1) · Chen Wang, PhD,MD (1) · Christian Gerloff, MD (1) · Clive Kearon, MB, MRCP, FRCP(C), PhD (1) · Daniel F Hanley, MD (1) · Fana Alemseged, MD, PhD (1) · Goetz Thomalla, MD (1) · Horiana Grosu, M D (1)
PMID 22435369, PMID 29694815, PMID 29766770, PMID 38907679, PMID 16574919, PMID 19233036, PMID 19741062, PMID 20047905, PMID 20185783, PMID 20651267, PMID 20667989, PMID 21940973, PMID 22382155, PMID 22474059, PMID 23370203, PMID 23418571, PMID 23463422, PMID 23537968, PMID 23887841, PMID 24324944, PMID 25517348, PMID 25671797, PMID 25671798, PMID 25677596, PMID 25726502, PMID 25882376, PMID 25882510, PMID 26228884, PMID 26243227, PMID 26898852, PMID 27462117, PMID 28081952, PMID 28174327, PMID 28425349, PMID 28780236, PMID 28842449, PMID 28844990, PMID 28887375, PMID 28928186, PMID 29211671, PMID 29367334, PMID 30586751, PMID 30699446, PMID 30739747, PMID 31067369, PMID 31161343, PMID 31177984, PMID 31354089, PMID 31571176, PMID 31592728
P50NS044148 (1), U01HL088476 (1), U01NS062851 (1), U01NS080824 (1)